Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Core Points - The company held its second extraordinary general meeting of shareholders in 2025 on July 31, 2025, with a total of 978 shareholders present, representing 3,210,215,774 shares, which is 48.8419% of the total voting shares [3][4] - The meeting approved the appointment of the accounting firm for the 2025 fiscal year with 99.1053% of the votes in favor, and a special resolution to amend the company's articles of association with 90.2621% approval [7][8] Meeting Details - The meeting was held at the Nanjiao Hotel in Shanghai and combined on-site and online voting methods [3] - The meeting was convened by the sixth board of directors and presided over by the vice chairman and general manager, Jun Xu [3] Attendance - A total of 973 minority shareholders participated, representing 798,538,266 shares, which is 12.1494% of the total voting shares [6] - The total share capital of the company as of the registration date was 6,637,984,837 shares, with 65,321,952 shares held in the repurchase account excluded from voting rights [6] Voting Results - The proposal to appoint the accounting firm received 3,181,494,720 votes in favor, with only 27,235,854 votes against [7] - The special resolution to amend the articles of association received 2,897,608,048 votes in favor, with 311,532,426 votes against [8] Legal Opinion - The legal opinion provided by King & Wood Mallesons confirmed that the meeting's procedures complied with relevant laws and regulations, and the voting results were valid [10]

北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》 （以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《上海莱士血液制品股份有限公司章程》 （以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 7 月 31 日召 开的 2025 年第二次临时股东大会（以下简称本次股东大会），并就本次股东大 会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 海莱士血液制品股份有限公司第六届董事会第十二次（临时）会议决议 的公告》； 公司已向本所保证，公司已向本所提供了 ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，上海莱士发布公告称，公司2025年第二次临时股东大会于2025年7月31日 召开，审议通过了《关于聘任2025年度会计师事务所的议案》等。 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-055 上海莱士血液制品股份有限公司 2025 年第二次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次会议提案涉及股东大会特别决议事项，按照《公司章程》规定，本次特 别决议事项需经出席会议股东（包括股东代理人）所持表决权 3/4 以上表决同意后方 可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2025 年 7 月 31 日（星期四）14:00； 网络投票时间为：2025 年 7 月 31 日（星期四）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 31 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025 年 7 月 31 日 9:15 至 15:00 期间的任意时 间； 2、现场会议召开 ...

1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 7 月 16 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届董事会第十二次（临时）会议决议 的公告》； 3. 公司 2025 年 7 月 16 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届监事会第七次会议决议的公告》； 公司已向本所保证，公司已向本所提供了本所为出具本法律意见书所要求 公司提供的原始书面材料、副本材料、复印材料、承诺函或证明，并无隐瞒记 载、虚假陈述和重大遗漏之处；公司提供给本所的文件和材料是真实、准确、 完整和有效的，且文件材料为副本或复印件的，其与原件一致和相符。 北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《 ...

金融界消息 截至2025年7月30日收盘，上海莱士（002252）报收于6.99元，下跌0.43%，换手率0.96%， 成交量63.45万手，成交金额4.45亿元。 天眼查商业履历信息显示，上海莱士血液制品股份有限公司，成立于1988年，位于上海市，是一家以从 事医药制造业为主的企业。企业注册资本663798.4837万人民币，实缴资本663798.4837万人民币。公司 法定代表人为Jun Xu。 通过天眼查大数据分析，上海莱士血液制品股份有限公司共对外投资了25家企业，参与招投标项目690 次，知识产权方面有商标信息40条，专利信息38条，此外企业还拥有行政许可360个。 来源：金融界 资金流向方面，今日主力资金净流出3894.84万元，占比成交额8.75%。其中，超大单净流出1717.01万 元、占成交额3.86%，大单净流出2177.83万元、占成交额4.89%，中单净流出流入690.60万元、占成交 额1.55%，小单净流入3204.24万元、占成交额7.2%。 上海莱士最新一期业绩显示，截至2025一季报，公司营业总收入20.06亿元、同比减少2.45%，归属净利 润5.66亿元，同比减少25.2 ...

Core Viewpoints - The pharmaceutical and biotechnology sector is experiencing a turning point and structural market trends in the first half of 2025, with a focus on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces as structural opportunities [3][5] - The A-share pharmaceutical and biotechnology index has increased by 10.10% since the beginning of 2025, outperforming the CSI 300 index by 8.90 percentage points, ranking 4th in industry performance [3][22] - Among 480 listed pharmaceutical and biotechnology companies, 348 have seen their stock prices rise, accounting for 72.5%, with 17 stocks doubling in value [3][40] Investment Logic - The innovative drug sector is accelerating its value reconstruction through business development (BD) overseas, research and commercialization progress, and policy support. In the first half of 2025, over 50 BD transactions for innovative drugs occurred, totaling over $48 billion [5] - Significant clinical data releases and commercialization progress for major drug candidates are expected to drive stock price increases [5] - Policy initiatives, such as the March 2025 government work report emphasizing the support for innovative drugs and medical devices, are providing strong backing for the industry's long-term development [5] Market Performance - The pharmaceutical sector's valuation has seen a short-term recovery but remains at a long-term low, with a PE ratio of 29 times as of mid-2025, slightly above the 50th percentile of the past four years [3][43] - Public fund holdings in the pharmaceutical sector have increased, with the proportion of public funds in A+H shares rising to 9.05% in Q1 2025, a 0.37 percentage point increase [3][58] Sub-industry Performance - The best-performing sub-industries in the pharmaceutical sector include chemical preparations and other biological products, with increases of 25.8% and 24.0%, respectively [3][22] - The pharmaceutical industry is witnessing a structural market trend, with innovative drugs leading the charge, while traditional sectors like vaccines and traditional Chinese medicine have seen slight declines [3][29] Recommended Stocks - A robust portfolio is suggested, including companies such as Heng Rui Medicine, BeiGene, and United Imaging Healthcare, among others [10]

Production Capacity and Resource Matching - The company has six production bases located in Shanghai, Hefei, Hengyang, Zhengzhou, Wenzhou, and Nanning, with Shanghai, Hefei, and Hengyang being the largest [2] - Current production capacity matches the plasma collection volume, with ongoing expansion projects, such as the Shanghai base, designed to increase capacity to over 1,500 tons per year [2] Plasma Station and Resource Development - Prior to the acquisition of Nanyue Biological, the company had a total of 44 plasma collection stations, with Nanyue adding 9 more, distributed across 11 provinces [3] - The company focuses on both optimizing existing plasma stations and expanding new ones to ensure continuous growth in plasma collection [4] Market Conditions and Product Demand - The blood product market currently has a certain level of inventory among companies and distributors [5] - Sales of human albumin have slightly slowed due to healthcare policies and supply-demand dynamics, but there remains a rigid demand for its various medical applications [6] Pricing and Innovation - Blood product prices have experienced slight changes influenced by policy and supply-demand factors, with the company monitoring market dynamics to maintain reasonable pricing [7] - The company is committed to innovation, focusing on both "plasma expansion" and "plasma extraction," with ongoing clinical research on SR604 injection, currently in Phase IIb trials [8] Strategic Partnerships - In March 2019, the company signed an exclusive strategic cooperation agreement with Klibor, leading to collaborative efforts in quality management and product distribution, positively impacting performance [9]